Uncategorized

An eye drug biotech banks $118M and stocks its executive suite

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

​Read More

Published

on

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version